Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
25
05
2023
accepted:
20
10
2023
revised:
29
08
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
We aimed to evaluate the predictors of sustainability of biologic drugs for paediatric patients with Crohn's disease (CD). The Czech National Prospective Registry of Biologic and Targeted Therapy of Inflammatory Bowel Disease (CREdIT) was used to identify the biologic treatment courses in paediatric patients with CD. Mixed-effects Cox models and propensity score analyses were employed to evaluate predictors of treatment sustainability. Among the 558 observations of 473 patients, 264 were treated with adalimumab (47%), 240 with infliximab (43%), 41 with ustekinumab (7%), and 13 with vedolizumab (2%). Multivariable analysis revealed higher discontinuation risk with infliximab compared to adalimumab (HR = 0.600, 95%CI 0.389-0.926), both overall and in first-line treatment (HR = 0.302, 95%CI 0.103-0.890). Infliximab versus adalimumab was associated with shorter time to escalation (HR = 0.094, 95%CI 0.043-0.203). Propensity-score analysis demonstrated lower sustainability of infliximab (HR = 0.563, 95%CI 1.159-2.725). The time since diagnosis to treatment initiation (HR = 0.852, 95%CI 0.781-0.926) was the most important predictor. Baseline immunosuppressive therapy prolonged sustainability with infliximab (HR = 2.899, 95%CI 1.311-6.410). Given the results suggesting shorter sustainability, the need for earlier intensification and thus higher drug exposure, and the greater need for immunosuppression with infliximab than with adalimumab, the choice of these drugs cannot be considered completely equitable. Our study identified predictors of sustainability of biologic treatment in paediatric patients with Crohn's disease, including adalimumab (versus infliximab), early initiation of biologic treatment, and normalised baseline haemoglobin levels. Infliximab treatment was associated with earlier intensification, higher drug exposure, and a greater need for immunosuppression. Parents and patients should be fully informed of the disadvantages of intravenous infliximab versus adalimumab during the decision-making process. This study emphasises the importance of not delaying the initiation of biologic therapy in paediatric patients with Crohn's disease.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to evaluate the predictors of sustainability of biologic drugs for paediatric patients with Crohn's disease (CD).
METHODS
METHODS
The Czech National Prospective Registry of Biologic and Targeted Therapy of Inflammatory Bowel Disease (CREdIT) was used to identify the biologic treatment courses in paediatric patients with CD. Mixed-effects Cox models and propensity score analyses were employed to evaluate predictors of treatment sustainability.
RESULTS
RESULTS
Among the 558 observations of 473 patients, 264 were treated with adalimumab (47%), 240 with infliximab (43%), 41 with ustekinumab (7%), and 13 with vedolizumab (2%). Multivariable analysis revealed higher discontinuation risk with infliximab compared to adalimumab (HR = 0.600, 95%CI 0.389-0.926), both overall and in first-line treatment (HR = 0.302, 95%CI 0.103-0.890). Infliximab versus adalimumab was associated with shorter time to escalation (HR = 0.094, 95%CI 0.043-0.203). Propensity-score analysis demonstrated lower sustainability of infliximab (HR = 0.563, 95%CI 1.159-2.725). The time since diagnosis to treatment initiation (HR = 0.852, 95%CI 0.781-0.926) was the most important predictor. Baseline immunosuppressive therapy prolonged sustainability with infliximab (HR = 2.899, 95%CI 1.311-6.410).
CONCLUSIONS
CONCLUSIONS
Given the results suggesting shorter sustainability, the need for earlier intensification and thus higher drug exposure, and the greater need for immunosuppression with infliximab than with adalimumab, the choice of these drugs cannot be considered completely equitable.
IMPACT
CONCLUSIONS
Our study identified predictors of sustainability of biologic treatment in paediatric patients with Crohn's disease, including adalimumab (versus infliximab), early initiation of biologic treatment, and normalised baseline haemoglobin levels. Infliximab treatment was associated with earlier intensification, higher drug exposure, and a greater need for immunosuppression. Parents and patients should be fully informed of the disadvantages of intravenous infliximab versus adalimumab during the decision-making process. This study emphasises the importance of not delaying the initiation of biologic therapy in paediatric patients with Crohn's disease.
Identifiants
pubmed: 38012309
doi: 10.1038/s41390-023-02913-7
pii: 10.1038/s41390-023-02913-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Qiu, Y. et al. Systematic review with meta-analysis: loss of response and requirement of Anti-Tnfalpha dose intensification in Crohn’s Disease. J. Gastroenterol. 52, 535–554 (2017).
doi: 10.1007/s00535-017-1324-3
pubmed: 28275925
Schultheiss, J. P. D. et al. Loss of response to Anti-Tnfalpha agents depends on treatment duration in patients with inflammatory bowel disease. Aliment. Pharm. Ther. 54, 1298–1308 (2021).
doi: 10.1111/apt.16605
Bronsky, J. et al. Adalimumab vs infliximab in pediatric patients with Crohn’s disease: a propensity score analysis and predictors of treatment escalation. Clin. Transl. Gastroenterol. 13, e00490 (2022).
doi: 10.14309/ctg.0000000000000490
pubmed: 35363628
pmcid: 9132518
Kaplan, J. L. et al. Use, durability, and risks for discontinuation of initial and subsequent biologics in a large pediatric-onset Ibd Cohort. J. Pediatr. Gastroenterol. Nutr. 76, 566–575 (2023).
doi: 10.1097/MPG.0000000000003734
pubmed: 36804501
pmcid: 10097486
Jongsma, M. M. E. et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s Disease: an open-label multicentre randomised controlled trial. Gut 71, 34–42 (2022).
doi: 10.1136/gutjnl-2020-322339
pubmed: 33384335
Lauriot Dit Prevost, C. et al. Bowel damage and disability in crohn’s disease: a prospective study in a tertiary referral centre of the lemann index and inflammatory bowel disease disability index. Aliment. Pharm. Ther. 51, 889–898 (2020).
doi: 10.1111/apt.15681
Kerur, B. et al. Biologics delay progression of Crohn’s disease, but not early surgery, in children. Clin. Gastroenterol. Hepatol. 16, 1467–1473 (2018).
doi: 10.1016/j.cgh.2018.02.027
pubmed: 29486253
Powers JM. Approach to the child with anemia. In: UpToDate, Post TW (Ed), Wolters Kluwer. https://www.uptodate.com . (Accessed on July 20, 2023).
Singh, S. et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 14, 1120–1129.e1126 (2016).
doi: 10.1016/j.cgh.2016.03.038
pubmed: 27058635
pmcid: 4955682
Di Domenicantonio, R. et al. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin. Epidemiol. 10, 203–213 (2018).
doi: 10.2147/CLEP.S150030
pubmed: 29440933
pmcid: 5804123
Ananthakrishnan, A. N. et al. Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis. 22, 880–885 (2016).
doi: 10.1097/MIB.0000000000000754
pubmed: 26933751
Nuti, F. et al. Prospective evaluation of the achievement of mucosal healing with Anti-Tnf-Alpha therapy in a paediatric Crohn’s disease cohort. J. Crohns Colitis 10, 5–12 (2016).
doi: 10.1093/ecco-jcc/jjv126
pubmed: 26188350
Li, S., Reynaert, C., Su, A. L. & Sawh, S. Efficacy and safety of infliximab in pediatric crohn disease: a systematic review and meta-analysis. Can. J. Hosp. Pharm. 72, 227–238 (2019).
pubmed: 31258168
Atia, O. et al. Dop45 utilization and sustainability of biologics in Cd - a nationwide study from the Epi-Iirn. J. Crohn’s Colitis 15, S082–S083 (2021).
doi: 10.1093/ecco-jcc/jjab073.084
Hyams, J. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s Disease in children. Gastroenterology 132, 863–873 (2007).
doi: 10.1053/j.gastro.2006.12.003
pubmed: 17324398
Hyams, J. S. et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143, 365–374.e362 (2012).
doi: 10.1053/j.gastro.2012.04.046
pubmed: 22562021
Schreiber, S. et al. Randomized controlled trial: subcutaneous vs intravenous infliximab Ct-P13 maintenance in inflammatory bowel disease. Gastroenterology 160, 2340–2353 (2021).
doi: 10.1053/j.gastro.2021.02.068
pubmed: 33676969
Bittner, B., Richter, W. & Schmidt, J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 32, 425–440 (2018).
doi: 10.1007/s40259-018-0295-0
pubmed: 30043229
pmcid: 6182494
Sandborn, W. J. et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 158, 562–572.e512 (2020).
doi: 10.1053/j.gastro.2019.08.027
pubmed: 31470005
Baumgart, D. C. & Le Berre, C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N. Engl. J. Med. 385, 1302–1315 (2021).
doi: 10.1056/NEJMra1907607
pubmed: 34587387
Matsumoto, T. et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J. Crohns Colitis 10, 1259–1266 (2016).
doi: 10.1093/ecco-jcc/jjw152
pubmed: 27566367
Colombel, J. F. et al. Infliximab, Azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362, 1383–1395 (2010).
doi: 10.1056/NEJMoa0904492
pubmed: 20393175
Colombel, J. F. et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin. Gastroenterol. Hepatol. 17, 1525–1532.e1521 (2019).
doi: 10.1016/j.cgh.2018.09.033
pubmed: 30267864
Feagan, B. G. et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s Disease. Gastroenterology 146, 681–688 e681 (2014).
doi: 10.1053/j.gastro.2013.11.024
pubmed: 24269926
Kierkus, J. et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn Disease. J. Pediatr. Gastroenterol. Nutr. 60, 580–585 (2015).
doi: 10.1097/MPG.0000000000000684
pubmed: 25564804
Hamdeh, S. et al. Early vs late use of anti-tnfa therapy in adult patients with crohn disease: a systematic review and meta-analysis. Inflamm. Bowel Dis. 26, 1808–1818 (2020).
doi: 10.1093/ibd/izaa031
pubmed: 32064534
van Rheenen, P. F. et al. The medical management of paediatric Crohn’s disease: an ecco-espghan guideline update. J. Crohns Colitis 15, 171–194 (2020).
doi: 10.1093/ecco-jcc/jjaa161
Hradsky, O. et al. Risk factors for dermatological complications of Anti-Tnf therapy in a cohort of children with Crohn’s disease. Eur. J. Pediatr. 180, 3001–3008 (2021).
doi: 10.1007/s00431-021-04077-0
pubmed: 33876264
Freling, E. et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of Anti-Tnf therapy in inflammatory bowel disease: a 14-Year experience. Am. J. Gastroenterol. 110, 1186–1196 (2015).
doi: 10.1038/ajg.2015.205
pubmed: 26195181
Nigam, G. B., Bhandare, A. P., Antoniou, G. A. & Limdi, J. K. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur. J. Gastroenterol. Hepatol. 33, 346–357 (2021).
doi: 10.1097/MEG.0000000000001917
pubmed: 32889976
Hyams, J. S. et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm. Bowel Dis. 15, 816–822 (2009).
doi: 10.1002/ibd.20845
pubmed: 19107783
Sridhar, S., Maltz, R. M., Boyle, B. & Kim, S. C. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-tnf therapy. Inflamm. Bowel Dis. 24, 2086–2092 (2018).
doi: 10.1093/ibd/izy112
pubmed: 29718343
Lerchova, T. et al. Prediction of Thiopurine failure in pediatric crohn’s disease: pediatric ibd porto group of espghan. Pediatr Res. 93, 1659–1666 (2023).
doi: 10.1038/s41390-022-02270-x
pubmed: 36008595